Etcembly
PrivateLast Round
Series A
Extension
Dec 8, 2023
Est. Valuation
$29.9M
Total Funding Raised
$12.67M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Etcembly operates in Healthcare & Life Sciences and is based in Didcot. Its latest recorded funding round was a Series A Extension round in December 2023.
Etcembly is a biotechnology company that utilizes a proprietary generative AI platform, EMLy™, to discover and engineer T-cell receptor (TCR) immunotherapies for cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting, Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Etcembly Comparables
Compare Etcembly with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Exogene | 87% | |
| Engimmune Therapeutics | 83% | |
| T-Cypher Bio | 77% |
For institutional investors. Book with your work email.
Etcembly Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Dec 8, 2023 | ||||
| Series A | Dec 14, 2022 | ||||
| Seed | Apr 23, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Etcembly Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| iGlobe Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 178% MoM, reaching 4.4K.
- Mar 18, 2026
Collaboration with Avigen Ltd. has been a resounding success.
For institutional investors. Book with your work email.
Etcembly Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Etcembly's valuation, stock price, and market status.
Is Etcembly a public or private company?
Etcembly is a private company.
What is the current stock price of Etcembly?
Etcembly is a private company, so its shares have no public market price. Caplight tracks Etcembly's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Etcembly worth (valuation)?
Etcembly's valuation is estimated at $29.9M based on funding round data.
Can I buy Etcembly stock?
Etcembly shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Etcembly's last funding round?
Etcembly's most recent funding round was Series A Extension on December 8, 2023.
Who are the main investors in Etcembly?
Key investors in Etcembly include iGlobe Partners.
Will Etcembly IPO soon?
No public IPO plans have been announced for Etcembly.
How can I track Etcembly secondary market activity?
Caplight tracks bids, offers, and trades in Etcembly's shares on secondary markets.